|
 |
|
Investment Objective/Strategy - The First Trust NYSE Arca Biotechnology Index Fund is an exchange-traded index fund. The investment objective of the Fund is to replicate as closely as possible, before fees and expenses, the price and yield of the NYSE Arca Biotechnology IndexSM.
There can be no assurance that the Fund's investment objectives will be achieved.
-
The NYSE Arca Biotechnology IndexSM is an equal dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services.
-
Such processes include, but are not limited to, recombinant DNA technology, molecular biology, genetic engineering, monoclonal antibody-based technology, lipid/liposome technology, and genomics.
-
The index is rebalanced quarterly based upon closing prices on the third Friday in January, April, July & October to ensure that each component stock continues to represent an approximately equal weight in the index.
Ticker | FBT |
Fund Type | Biotechnology |
Investment Advisor | First Trust Advisors L.P. |
Investor Servicing Agent | Bank of New York Mellon |
CUSIP | 33733E203 |
ISIN | US33733E2037 |
Intraday NAV | FBTIV |
Fiscal Year-End | 12/31 |
Exchange | NYSE Arca |
Inception | 6/19/2006 |
Inception Price | $20.00 |
Inception NAV | $20.00 |
Rebalance Frequency | Quarterly |
Gross Expense Ratio* | 0.56% |
Net Expense Ratio* | 0.56% |
* As of 5/1/2018
Expenses are capped contractually at 0.60% per year, at least until April 30, 2019.
Closing NAV1 | $145.52 |
Closing Market Price2 | $145.52 |
Bid/Ask Midpoint | $145.56 |
Bid/Ask Premium | 0.02% |
Total Net Assets | $2,859,559,327 |
Outstanding Shares | 19,650,002 |
Daily Volume | 91,616 |
Average 30-Day Daily Volume | 151,026 |
Closing Market Price 52-Week High/Low | $159.14 / $114.50 |
Closing NAV 52-Week High/Low | $159.05 / $114.54 |
Number of Holdings | 30 |
Maximum Market Cap. | $117,879 |
Median Market Cap. | $8,189 |
Minimum Market Cap. | $1,224 |
Price/Book | 5.22 |
Price/Sales | 7.31 |
Holding |
Percent |
Charles River Laboratories International, Inc. |
3.92% |
Bio-Techne Corporation |
3.91% |
Ultragenyx Pharmaceutical Inc. |
3.74% |
Alexion Pharmaceuticals, Inc. |
3.66% |
IQVIA Holdings Inc. |
3.66% |
FibroGen, Inc. |
3.59% |
ACADIA Pharmaceuticals Inc. |
3.57% |
Incyte Corporation |
3.52% |
QIAGEN N.V. |
3.48% |
Celgene Corporation |
3.46% |
Holdings are subject to change.
Past performance is not indicative of future results.
Among 132 funds in the Health category. This fund was rated 4 stars/132 funds (3 years), 3 stars/121 funds (5 years), 4 stars/98 funds (10 years).
Number of Days Bid/Ask Midpoint Above NAV
Quarter Ended |
0-49 Basis Points |
50-99 Basis Points |
100-199 Basis Points |
>=200 Basis Points |
12/31/2018 |
34 |
1 |
2 |
0 |
9/30/2018 |
34 |
0 |
0 |
1 |
6/30/2018 |
35 |
0 |
0 |
0 |
3/31/2018 |
53 |
0 |
0 |
0 |
Number of Days Bid/Ask Midpoint Below NAV
Quarter Ended |
0-49 Basis Points |
50-99 Basis Points |
100-199 Basis Points |
>=200 Basis Points |
12/31/2018 |
23 |
3 |
0 |
0 |
9/30/2018 |
28 |
0 |
0 |
0 |
6/30/2018 |
29 |
0 |
0 |
0 |
3/31/2018 |
8 |
0 |
0 |
0 |
The price used to calculate market return is determined by using the midpoint between the highest bid and the lowest offer on the stock exchange, on which shares of the Fund are listed for trading, as of the time that the Fund's NAV is calculated.
|
Standard Deviation |
Alpha |
Beta |
Sharpe Ratio |
Correlation |
FBT |
23.80% |
-2.50 |
1.69 |
0.80 |
0.80 |
NASDAQ Biotechnology Index |
21.87% |
-10.06 |
1.48 |
0.40 |
0.76 |
S&P Composite 1500 Health Care Index |
13.11% |
-0.03 |
0.97 |
0.94 |
0.83 |
S&P 500 Index |
11.18% |
--- |
1.00 |
1.14 |
1.00 |
Standard Deviation is a measure of price variability (risk). Alpha is an indication of how much an investment outperforms or underperforms
on a risk-adjusted basis relative to its benchmark.Beta is a measure of price variability relative to the market. Sharpe Ratio is a measure
of excess reward per unit of volatility. Correlation is a measure of the similarity of performance.
NASDAQ Biotechnology Index - The Index includes securities of NASDAQ-listed companies classified as either Biotechnology or Pharmaceuticals which also meet other eligibility criteria. S&P Composite 1500 Health Care Index - The Index is a capitalization-weighted index of companies classified by GICS as health care within the S&P Composite 1500 Index. S&P 500 Index - The Index is an unmanaged index of 500 stocks used to measure large-cap U.S. stock market performance.
|
|
The information presented is not intended to constitute an investment recommendation for, or advice to, any specific person. By providing this information, First Trust is not undertaking to give advice in any fiduciary capacity within the meaning of ERISA and the Internal Revenue Code. First Trust has no knowledge of and has not been provided any information regarding any investor. Financial advisors must determine whether particular investments are appropriate for their clients. First Trust believes the financial advisor is a fiduciary, is capable of evaluating investment risks independently and is responsible for exercising independent judgment with respect to its retirement plan clients.
|